TMEM14B

Across TCGA pan-cancer cohorts, TMEM14B RNA is linked to patient survival in 27 of 34 cancer types, making it the most broadly survival-associated TMEM14B data layer compared with 1 for mutation status.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher TMEM14B RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMEM14B expression acts as an unfavorable survival marker, although some lineages such as OV and THYM show a favorable association.

LIHC, KIRP, and KICH are the cancer types where TMEM14B RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.464	0.615	<.001	71	view →
KIRP	OS	Quartile	All	0.848	0.980	<.001	62	view →
KICH	OS	Tertile	II,III,IV	0.511	1.000	<.001	57	view →
UVM	DFS	Tertile	III,IV	0.237	1.000	.001	50	view →
ACC	DFS	Median	All	0.277	0.653	.001	45	view →
OV	OS	Median	III,IV	0.367	0.271	<.001	40	view →
ESCA	DFS	Tertile	III,IV	0.263	0.602	.001	39	view →
SARC	OS	Tertile	All	0.359	0.636	<.001	28	view →
THYM	OS	Tertile	II,III,IV	1.000	0.830	.007	28	view →
BRCA	DFS	Median	All	0.965	0.933	.002	26	view →
STAD	OS	Quartile	All	0.460	0.751	.007	21	view →
UCEC	DFS	Tertile	All	0.614	0.842	<.001	18	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 27 lineages.

TMEM14B–LIHC (DFS)

Open the LIHC breakdown →